Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29216509 | 0.86 | NOX1 (0.43) | MAOABCHESNCAMEN1CYP1A2 | |
| SCHEMBL4274211 | 0.82 | GAA (0.41) | MAOABCHESNCAMEN1CYP1A2 | |
| SCHEMBL28587851 | 0.74 | ALOX5 (0.36) | PTGS2 | |
| SCHEMBL1395944 | 0.73 | MAOA (0.33) | MAOABCHESNCAMEN1CYP1A2 | |
| SCHEMBL29310393 | 0.73 | MAOA (0.33) | MAOABCHESNCAMEN1CYP1A2 | |
| SCHEMBL2749161 | 0.73 | ALDH1A1 (0.42) | MAOAMEN1MAPTKMT2A | |
| SCHEMBL9979 | 0.73 | ALOX5 (0.30) | MAOA | |
| SCHEMBL25458 | 0.73 | NOX1 (0.59) | MAOABCHESNCAMEN1CYP1A2 | |
| Thianthrene SCHEMBL7786 | 0.72 | BCHE (0.56) | MAOABCHESNCAMEN1CYP1A2 | |
| SCHEMBL21629348 | 0.72 | BCHE (0.56) | MAOABCHESNCAMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984079-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES | Power Oleds Limited (GB) | 2016-02-17 | — | — | EP | claimed |
| WO-2014167286-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES | POWER OLEDS LIMITED (GB) | 2014-10-16 | — | — | WO | claimed |
| US-7674816-B2 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, LLC (US) | 2010-03-09 | — | — | US | claimed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | claimed |
| EP-1701718-A4 | SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE LLC (US) | 2009-06-24 | — | — | EP | claimed |
| EP-2032594-A1 | GLYCYRRHETINIC ACID DERIVATIVES | Wellington Laboratories Inc. (CA) | 2009-03-11 | — | — | EP | claimed |
| US-7432296-B2 | Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2008-10-07 | — | — | US | claimed |
| WO-2008000070-A1 | GLYCYRRHETINIC ACID DERIVATIVES | WELLINGTON LABORATORIES INC. (CA) | 2008-01-03 | — | — | WO | claimed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | claimed |
| US-20070191463-A1 | Substituted melatonin derivatives, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (CA) | 2007-08-16 | — | — | US | claimed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | claimed |
| EP-1596856-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS AND/OR SUBSTITUTED 2-HETEROARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| WO-2005062992-A2 | SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC (US) | 2005-07-14 | — | — | WO | claimed |
| WO-2004071381-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS AND/OR SUBSTITUTED 2-HETEROARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| CN-1144526-A | Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents | NISSAN CHEMICAL IND LTD (JP) | 1997-03-05 | — | — | CN | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| EP-0167820-B1 | PROCESS FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED BENZ(C,D)-INDOL-2-ONES (NAPHTHOLACTAMES) | BAYER AG (DE) | 1989-04-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | MAOA 3288/4885BCHE 4393/4885SNCA 4761/4885 |
| US-20070191463-A1 | Substituted melatonin derivatives, process for their preparation, and methods of use | MTNR1B, MTNR1A, CYP3A5 | MAOA 192/4885BCHE 2562/4885SNCA 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.